FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	• • • • •
1. Name and Address of Reporting Person* $Rosa David A$	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person			2. Issuer Name and Ticker or Trading Symbol BioRestorative Therapies, Inc. [BRTX]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle)				X	Director	10% Owner				
					Officer (give title below)	Other (specify below)				
		(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		below)	Delow)				
C/O BIORESTOR	RATIVE THERA	APIES, INC.	02/17/2023							
40 MARCUS DR	IVE, SUITE ON	E								
(Street)	4. If Amendment, Date of Original Filed (Month/Day/Year)		6. Indivi	6. Individual or Joint/Group Filing (Check Applicable Line)						
MELVILLE	X Form filed by One Rev		orting Person							
	IN 1	11/4/			Form filed by More than	n One Reporting Person				
(City)	(State) (Zip)									

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	Date Ex (Month/Day/Year) if a	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Securities	(Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount	(A) or (D)	Price	3 and 4)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Sole (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		re es i(A)or dof	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option	\$5.08							(1)	11/04/2031	Common Stock	10,490		10,490	D	
Stock Option	\$2.91	02/17/2023		Α		32,028		(2)	02/17/2033	Common Stock	32,028	\$ <mark>0</mark>	32,028	D	

Explanation of Responses:

1. The option vests and becomes exercisable in eight nearly-equal, quarterly installments beginning on February 4, 2022 and continuing every three months thereafter until fully vested.

2. The option vests and becomes exercisable in twelve monthly installments of 2,669 shares beginning on March 17, 2023 and continuing every month thereafter until fully vested.

/s/ David A. Rosa

** Signature of Reporting Person

02/17/2023 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.